Skip to main navigation
Telix Pharmaceuticals Limited Logo
  • Overview
  • News
  • Events & Presentations
    • Events
    • Presentations
  • Financials
    • Half-year & Quarterly Results
    • Annual Reports & AGMs
    • ASX Announcements
    • SEC Filings
  • Pipeline
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Board & Management
    • Documents & Charters
    • Sustainability
  • Resources
    • Shareholder Information
    • Investor Resources
    • Email Alerts
    • Contact Us

ASX Announcements

Date Title
23 Jan 2026
Ceasing to be a substantial holder
20 Jan 2026
Telix Achieves FY25 Guidance - US$804M, Q4 Growth
20 Jan 2026
Chinese NMPA Accepts New Drug Application for Illuccix
14 Jan 2026
Appendix 2A updated
13 Jan 2026
Notification of cessation of securities - TLX
12 Jan 2026
Telix JP Morgan Healthcare Conference 2026 Presentation
  • First page «
  • Previous page ‹
  • …
  • Page 2
  • Page 3
  • Current page 4
Displaying 31 - 36 of 36

Subscribe to our Email Alerts

©2026 Telix Pharmaceuticals Limited.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. This website is intended for corporate communication and investor relations purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Forward Looking Statements
  • Twitter
  • LinkedIn
  • Facebook
  • YouTube
Search Investors